Lung cancer
Conditions
Interventions
CRET Testing group:None
Sponsors
Jilin Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients aged 18 years and above, newly diagnosed and treatment-naive with pathologically confirmed primary lung cancer at tumor stage IIb-IV; 2.Sign a written informed consent form to voluntarily participate in the study and cooperate with follow-up completion; 3.Lung cancer patients who are receiving or planning to receive anti-tumor treatment in accordance with standard guidelines;
Exclusion criteria
Exclusion criteria: 1.Inpatients receiving surgical treatment as part of the lung cancer treatment regimen; 2.Patients receiving anticoagulant therapy such as vitamin K antagonists, direct oral anticoagulants of the heparin class, and fondaparinux due to various reasons; 3.Patients diagnosed with VTE within 48 hours after admission; 4.Patients hospitalized due to thrombosis this time; 5.Persons with mental illnesses or those who cannot cooperate subjectively; 6.History of VTE, acute coronary syndrome or cerebral infarction within the previous 6 months; 7.Have participated in similar trials or are undergoing other clinical trials;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet activation markers (CD62P, ADP-stimulated CD62P, ADP-stimulated CD62P/CD62P ratio); | — |
Secondary
| Measure | Time frame |
|---|---|
| Thrombotic events (venous thromboembolism or arterial thrombosis);Risk of tumor metastasis and clinical prognosis in cancer patients;Endpoint events (all-cause mortality or lost to follow-up);Baseline characteristics (age, sex, smoking history);Tumor characteristics (histological type, TNM stage, driver gene mutations);Laboratory parameters (platelet count);AUC of ROC curve; | — |
Countries
China
Contacts
Public ContactLiu Haifeng
Jilin Cancer Hospital
Outcome results
None listed